Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergan, Inc.
Allergan Receives FDA Approval for OZURDEX™ Biodegradable, Injectable Steroid Implant with Extended Drug Release for Retinal Disease
July 10th, 2009
Allergan, Inc. (NYSE: AGN) announced that the United States Food and Drug Administration (FDA) has approved OZURDEX™ (dexamethasone intravitreal implant) 0.7 mg as the first drug therapy indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Retinal vein occlusion (RVO), including BRVO and CRVO, is the second most common retinal vascular disease after diabetic retinopathy1 and is a significant cause of vision loss. OZURDEX™ is a first-of-its kind therapy administered via intravitreal injection delivering dexamethasone, a highly potent corticosteroid, via Allergan's proprietary and innovative...
Source: Health Business Week (2009-07-10)
|
